Antiviral Drug News and Research

RSS

An antiviral regimen based on biomimetic polymers for COVID-19

In a new study published on the bioRxiv* preprint server, scientists proposed the aforementioned mechanism of action (MOA) and have validated it using electron photomicrographs of murine cytomegalovirus (MCMV), which were incubated with a nanoviricide.

30 Nov 2021

Study on molnupiravir precursor NHC antiviral activity against SARS-CoV-2 variants of concern

In a new study, published on the bioRxiv* preprint server, scientists aimed to determine the reaction of the molnupiravir parent drug (NHC) to different SARS-CoV-2 Variants of Concern (VoCs). They also sought to establish the therapeutic window in a human lung cell model.

29 Nov 2021

Using metal nanoparticles to fight SARS-CoV-2

A recent review article looks at the potential of nanotechnology in fighting severe acute respiratory syndrome 2 (SARS-CoV-2), with several possibilities of strategies in therapeutics, vaccines, and prevention.

25 Nov 2021

Success of covid antiviral pills hinges on access to speedy and accurate tests

Within a few weeks, perhaps before many Americans finish decorating for the holidays, the U.S. could have access to a new antiviral pill from Merck expected to alter the deadly trajectory of the covid-19 pandemic — with a second option from Pfizer to follow shortly after.

22 Nov 2021

Modeling the role of antivirals in suppressing the COVID-19 pandemic

A new study used an agent-based mathematical model to evaluate potential population impact on the widespread use of antiviral treatment for reducing viral load and hospitalization risk.

16 Nov 2021

First detection of SARS-CoV-2 remdesivir resistance in an immunocompromised patient

A research group from the US (led by experts from Yale University School of Medicine) recently presented a case of an immunocompromised female patient with acquired deficiency of B lymphocytes who subsequently developed a protracted course of the infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

10 Nov 2021

Stenoparib effectively inhibits SARS-CoV-2 variants in vitro

A new study assesses the antiviral activity of stenoparib against four SARS-CoV-2 strains.

10 Nov 2021

Cell-based viral replication system for screening of SARS-CoV-2 drugs

The current study reports a SARS-CoV-2 replicon system within stable cell lines that can be cultured with ease in a standard biosafety level 2 laboratory.

10 Nov 2021

COVID-19 drug candidate with wide-ranging antiviral activity

A new study investigated the antiviral activity and mechanism of action of Brilacidin against multiple human coronaviruses.

9 Nov 2021

Hemin as a potential therapy for COVID-19

The current study explores the antiviral activity of HO-1 induced by hemin against SARS-CoV-2 and attempts to describe the mechanism of its anti-viral action.

8 Nov 2021

Pacific oyster as a weapon against SARS-CoV-2

According to an article published in the journal Reviews in Medical Virology, the effectiveness of mollusc-derived antiviral agents has been proven in many different laboratory and animal studies, while its efficacy against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has also been proposed by recent in silico studies.

7 Nov 2021

A novel approach to improve the stability of Remdesivir

A recent study discusses a novel method to enhance the stability of Remdesivir.

28 Oct 2021

The biochemical mechanisms of remdesivir-mediated RNA synthesis inhibition

A new preprint suggests a fruitful approach to develop such drugs based on biochemical and molecular modeling studies of the drug remdesivir.

19 Oct 2021

KU Leuven researchers develop an ultrapotent inhibitor of dengue virus

Researchers at the KU Leuven Rega Institute and CD3 have developed an ultrapotent inhibitor of the dengue virus, which causes the tropical disease known as dengue.

6 Oct 2021

Hyperbranched polylysine nanopolymer as potential broad-spectrum antiviral against SARS-CoV-2

The findings from this study suggest that HPNs may inhibit viral replication and budding.

27 Sep 2021

A daily pill to treat covid could be just months away, scientists say

Within a day of testing positive for covid-19 in June, Miranda Kelly was sick enough to be scared. At 44, with diabetes and high blood pressure, Kelly, a certified nursing assistant, was having trouble breathing, symptoms serious enough to send her to the emergency room.

24 Sep 2021

SARS-CoV-2 genome signature leads to replicative advantage in presence of Remdesivir

A new study indicates that low-level resistance of SARS-CoV-2 to remdesivir is not widespread and dissimilar to other RNA viruses revealing evolutionary predictability of this pandemic virus.

22 Sep 2021

Study offers important evidence for the safety of stem cell transplants

Stem cell transplants do not lead to changes in the DNA of the donor cells. That's according to a new study, which provides important evidence for the safety of this procedure.

7 Sep 2021

Impact of colloidal aggregation in COVID-19 drug repurposing screens

A recent study investigated the influence of colloidal aggregation on early drug development in repurposing screens

3 Sep 2021

Could a plant metabolite in liverworts be a potent antiviral against SARS-CoV-2 and other RNA viruses?

A new study from the National Centre for Biotechnology and Medicinal Chemistry Institute suggests Mother Nature delivered — in the form of liverworts. They found that the bryophyte Marchantia polymorpha, also known as umbrella liverworts, could work as a potential antiviral treatment.

5 Aug 2021